{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T07:46:45Z","timestamp":1795247205681,"version":"4.10.3"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,15]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Compared to heparin, there is limited evidence of the benefits of bivalirudin in the patients with extracorporeal membrane oxygenation (ECMO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched for studies comparing bivalirudin anticoagulation with heparin anticoagulation in ECMO patients in the PubMed, Embase, and Cochrane Library databases from inception to March 28, 2024. ECMO patients were divided into the bivalirudin experimental group and the heparin control group. Collected data were mortality rate, duration of ECMO, successful decannulation rate, incidence of thrombotic events, incidence of bleeding events, activated partial thromboplastin time values, platelet transfusion requirements, and other indicators for ECMO patients in the bivalirudin and heparin groups. StataMP17 and RevMan 5.4 software for data analysis and visualization were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 11 papers that met the inclusion criteria were included. Compared to the traditional heparin anticoagulation group, the bivalirudin anticoagulation group had a lower mortality rate (odds ratios [OR]\u2005=\u20050.74, 95% confidence intervals [CI; 0.56, 0.99],\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20052.01,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.04) and incidence of thrombotic events (OR\u2005=\u20050.52, 95% CI [0.38, 0.71],\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20054.11,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.0001); meanwhile, the ECMO decannulation success rate (OR\u2005=\u20051.87, 95% CI [1.2, 2.92],\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20052.75,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.006) was higher, with statistically significant differences between the 2 groups. In ECMO patients, there were no significant differences between bivalirudin and heparin in terms of ECMO duration, incidence of bleeding events, platelet transfusion requirements, and activated partial thromboplastin time, with no statistical significance between the 2. Subgroup analysis suggested that the mortality rate in the veno-venous group was lower than that in the control group, but the difference was not statistically significant (OR\u2005=\u20050.52, 95% CI [0.27, 0.99],\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20051.99,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.05). The mortality rate in the non-veno-venous group was lower than that in the control group, with no statistically significant difference (OR\u2005=\u20050.82, 95% CI [0.61, 1.11],\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20051.26,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.21).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Bivalirudin anticoagulation significantly reduced the mortality rate and incidence of thrombotic events in ECMO patients, while significantly increasing the success rate of ECMO decannulation. However, due to clinical heterogeneity and institutional variability in monitoring and transfusion practices, these findings should be interpreted with caution. Further stratified research is needed to confirm these outcomes across different ECMO subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000042696","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T19:01:54Z","timestamp":1755543714000},"page":"e42696","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness and safety of bivalirudin anticoagulation therapy in adult patients receiving extracorporeal membrane oxygenation: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3592-1941","authenticated-orcid":false,"given":"Yunnan","family":"Hu","sequence":"first","affiliation":[{"name":"Emergency Department, Shenzhen Longgang Second People\u2019s Hospital, Shenzhen, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linchang","family":"Yu","sequence":"additional","affiliation":[{"name":"Intensive Care Medicine Department, Shenzhen University General Hospital, Shenzhen, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendian","family":"Yang","sequence":"additional","affiliation":[{"name":"Emergency Department, Shenzhen Longgang Second People\u2019s Hospital, Shenzhen, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/ALN.0000000000004843","article-title":"The story of ECMO.","volume":"140","author":"Bartlett","year":"2024","journal-title":"Anesthesiology"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00134-021-06514-y","article-title":"Extracorporeal cardiopulmonary resuscitation in adults: evidence and implications.","volume":"48","author":"Abrams","year":"2022","journal-title":"Intensive Care Med"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/MAT.0000000000001605","article-title":"Thrombosis in extracorporeal membrane oxygenation (ECMO) circuits.","volume":"68","author":"Figueroa Villalba","year":"2022","journal-title":"ASAIO J"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1053\/j.jvca.2018.07.045","article-title":"Bleeding, thrombosis, and transfusion with two heparin anticoagulation protocols in venoarterial ECMO patients.","volume":"33","author":"Mazzeffi","year":"2019","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1358863X19898253","article-title":"Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management.","volume":"25","author":"Hogan","year":"2020","journal-title":"Vasc Med"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0043-1761269","article-title":"Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia.","volume":"49","author":"Selvadurai","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/PCC.0000000000002384","article-title":"Evaluation of bivalirudin as an alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation.","volume":"21","author":"Hamzah","year":"2020","journal-title":"Pediatr Crit Care Med"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1051\/ject\/2023027","article-title":"Anticoagulation strategies in COVID-19 infected patients receiving ECMO support.","volume":"55","author":"Diaz","year":"2023","journal-title":"J Extra Corpor Technol"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/MAT.0000000000001723","article-title":"Bivalirudin versus unfractionated heparin in patients with cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation.","volume":"69","author":"Uricchio","year":"2023","journal-title":"ASAIO J"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/03913988221148763","article-title":"Comparison of bivalirudin versus heparin in adult extracorporeal membrane oxygenation anticoagulant therapy: a retrospective case-control study.","volume":"46","author":"Tong","year":"2023","journal-title":"Int J Artif Organs"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/ejh.14146","article-title":"Comparison of bleeding and thrombotic outcomes in veno-venous extracorporeal membrane oxygenation: heparin versus bivalirudin.","volume":"112","author":"Kartika","year":"2024","journal-title":"Eur J Haematol"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MAT.0000000000000691","article-title":"Evaluation of systemic heparin versus bivalirudin in adult patients supported by extracorporeal membrane oxygenation.","volume":"64","author":"Berei","year":"2018","journal-title":"ASAIO J"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.jvca.2012.07.019","article-title":"Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study.","volume":"27","author":"Pieri","year":"2013","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/CCM.0000000000005033","article-title":"Comparison of bivalirudin versus heparin for maintenance systemic anticoagulation during adult and pediatric extracorporeal membrane oxygenation.","volume":"49","author":"Seelhammer","year":"2021","journal-title":"Crit Care Med"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/CCM.0000000000004944","article-title":"Comparison of anticoagulation strategies in patients requiring venovenous extracorporeal membrane oxygenation: heparin versus bivalirudin.","volume":"49","author":"Rivosecchi","year":"2021","journal-title":"Crit Care Med"},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/MAT.0000000000001598","article-title":"Comparison of bivalirudin versus unfractionated heparin for anticoagulation in adult patients on extracorporeal membrane oxygenation.","volume":"68","author":"Sheridan","year":"2022","journal-title":"ASAIO J"},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"e0485","DOI":"10.1097\/CCE.0000000000000485","article-title":"Extracorporeal membrane oxygenation complications in heparin- and bivalirudin-treated patients.","volume":"3","author":"Giuliano","year":"2021","journal-title":"Critical Care Explorations"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jocs.14458","article-title":"Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation.","volume":"35","author":"Kaseer","year":"2020","journal-title":"J Card Surg"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/02676591211055971","article-title":"The physiology of extracorporeal membrane oxygenation: the Fick principle.","volume":"38","author":"Lim","year":"2023","journal-title":"Perfusion"},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1051\/ject\/202153245","article-title":"The effectiveness of three different curricular models to teach fundamental ECMO specialist skills to entry level perfusionists.","volume":"53","author":"Riley","year":"2021","journal-title":"J Extra Corpor Technol"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.athoracsur.2016.01.044","article-title":"Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin.","volume":"102","author":"Lim","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.trsl.2020.04.014","article-title":"Pathogenesis of heparin-induced thrombocytopenia.","volume":"225","author":"Arepally","year":"2020","journal-title":"Transl Res"},{"key":"R24-20260911","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0140-6736(18)31714-8","article-title":"Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.","volume":"392","author":"Valgimigli","year":"2018","journal-title":"Lancet"},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1053\/j.jvca.2019.08.022","article-title":"Role of bivalirudin for anticoagulation in adult perioperative cardiothoracic practice.","volume":"34","author":"Erdoes","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R26-20260911","first-page":"1015","article-title":"Revisiting the pharmacology of unfractionated heparin.","volume":"58","author":"Derbalah","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R27-20260911","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3390\/medicina58121783","article-title":"Anticoagulation management during extracorporeal membrane oxygenation-a mini-review.","volume":"58","author":"Bur\u0161a","year":"2022","journal-title":"Medicina"},{"key":"R28-20260911","doi-asserted-by":"crossref","first-page":"1237601","DOI":"10.3389\/fmed.2023.1237601","article-title":"Is it time to switch to bivalirudin for ECMO anticoagulation?","volume":"10","author":"Navaei","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MAT.0000000000001808","article-title":"Heparin versus bivalirudin for anticoagulation in adult extracorporeal membrane oxygenation: a systematic review and meta-analysis.","volume":"69","author":"Wieruszewski","year":"2023","journal-title":"ASAIO J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:02:31Z","timestamp":1789153351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":28,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042696","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"2024-07-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}